Fosamax Cost in New Mexico 2026: Alendronate Prices, Medicaid, and Savings Options

What Does Fosamax Actually Cost in New Mexico in 2026?

Generic alendronate sodium 70 mg tablets cost approximately $15 per month at New Mexico retail pharmacies when purchased without insurance. Branded Fosamax carries a manufacturer list price near $80 per month, though almost no cash-paying patient needs to pay that figure given generic availability. Discount platforms such as GoodRx routinely show prices between $9 and $18 for a four-tablet supply (one month) at Walgreens, CVS, Smith's, and Walmart locations across Albuquerque, Santa Fe, Las Cruces, and Rio Rancho.

Alendronate received FDA approval in 1995 for postmenopausal osteoporosis and has been available generically since 2008 [1]. That long generic history is the primary reason cash prices are so low relative to the branded product. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), demonstrated that alendronate reduced vertebral fracture risk by 47% (relative risk 0.53 to 95% CI 0.41 to 0.68, P<0.001) compared with placebo over three years [2]. Those results remain the clinical foundation for prescribing alendronate in postmenopausal women with low bone mineral density.

The standard dosing schedule is 70 mg orally once weekly, taken in the morning on an empty stomach with 8 oz of plain water, followed by 30 minutes of upright posture before eating [1]. This once-weekly regimen replaced the original daily 10 mg schedule and is the formulation you will find priced at roughly $15 per month at New Mexico retailers.

Prices shift by ZIP code. Rural New Mexico pharmacies in areas like Gallup, Roswell, and Farmington may show slightly higher cash prices (up to $22 per month) due to lower volume dispensing, though mail-order generics from national chains can bring costs back to the $10 to $15 range statewide [3].

Does New Mexico Medicaid Cover Fosamax or Generic Alendronate?

New Mexico Medicaid does not routinely place alendronate on an open-access formulary tier. Most New Mexico Medicaid managed-care organizations (MCOs), including Blue Cross Community Centennial and Presbyterian Centennial Care, require a prior authorization (PA) for alendronate prescriptions. Without PA approval, claims for alendronate are denied at the pharmacy counter.

The prior authorization criteria generally require documentation of a bone mineral density (BMD) T-score of -2.5 or below, or a T-score between -1.0 and -2.5 combined with a documented fragility fracture or a 10-year major osteoporotic fracture probability of 20% or higher by FRAX [4]. The FRAX algorithm, maintained by the World Health Organization Collaborating Centre for Metabolic Bone Diseases, calculates fracture probability using age, sex, BMI, and clinical risk factors [5].

Physicians submitting a PA to a New Mexico Medicaid MCO should attach the DXA (dual-energy X-ray absorptiometry) report and the FRAX output. The Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women (2019) states: "We recommend initiating pharmacological therapy in postmenopausal women with a hip T-score of -2.5 or lower, or who have had a prior hip or vertebral fracture" [6]. That language gives prescribers a direct guideline anchor for PA letters.

If PA is denied, the New Mexico Human Services Department (HSD) Medicaid program has an appeals process under 42 CFR 431.200. Patients have 90 days from a denial notice to file an appeal. Prescribers who document medical necessity citing the FIT trial data and Endocrine Society guidelines tend to see reversal rates above 60% based on general PA appeal patterns across state Medicaid programs [7].

Is Compounded Alendronate Legal in New Mexico?

Compounded alendronate is legal in New Mexico when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Federal law (21 U.S.C. 503A) permits compounding pharmacies to prepare individualized formulations for specific patients, provided the drug is not on the FDA's list of essentially-a-copy or withdrawn drugs for safety reasons [8]. Alendronate does not appear on that prohibited list as of 2025.

New Mexico's Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. A 503B outsourcing facility, which produces sterile products at scale without patient-specific prescriptions, would face a higher regulatory threshold and is not the typical compounding pathway for an oral bisphosphonate like alendronate.

The practical implication: a New Mexico prescriber can write a patient-specific compounded alendronate prescription if there is a documented clinical reason the commercially available tablet is not suitable. Common reasons include documented tablet intolerance, swallowing difficulties requiring a liquid formulation, or a need for a dose not commercially available. Some 503A pharmacies offer compounded alendronate at little to no cost to patients when funded through assistance programs, though this varies by pharmacy and patient eligibility.

Patients should confirm that any 503A pharmacy they use holds an active New Mexico Board of Pharmacy license before dispensing. The FDA's guidance on 503A compounding (issued 2018, updated 2023) specifies that bulk drug substances used in compounding must appear on a permitted list or meet specific clinical need criteria [9]. Prescribers writing compounded alendronate orders should document the clinical rationale clearly in the chart.

Which Insurance Plans Cover Alendronate in New Mexico, and at What Tier?

Most commercial insurance plans available through the New Mexico Health Insurance Exchange (beWellnm) and employer-sponsored plans in the state place generic alendronate on Tier 1 (preferred generic) or Tier 2 (non-preferred generic). At Tier 1, patient cost-sharing is typically $0 to $10 per month after meeting the deductible. Tier 2 cost-sharing ranges from $15 to $35 per month depending on plan design [3].

Branded Fosamax, when covered at all, typically sits at Tier 3 or Tier 4 on commercial formularies, with cost-sharing between $40 and $90 per month. Most pharmacy benefit managers (PBMs) operating in New Mexico have implemented generic-first edits that automatically substitute generic alendronate unless the prescriber specifies "dispense as written" and the plan covers the brand.

Medicare Part D plans sold in New Mexico for 2026 generally list alendronate 70 mg as a Tier 1 covered drug, meaning most Part D enrollees pay $0 to $5 per month after the deductible phase. The Inflation Reduction Act $2,000 out-of-pocket cap effective 2025 further reduces the financial exposure for Medicare beneficiaries who are also taking other medications [10].

Tricare beneficiaries at Kirtland Air Force Base or White Sands installations can obtain generic alendronate through the DoD pharmacy benefit at $0 copay via military treatment facility pharmacies or the TRICARE Mail Order Pharmacy (TMOP) [11].

How to Get the Cheapest Alendronate in New Mexico

Several strategies reliably bring the monthly cost of alendronate below $15 in New Mexico.

GoodRx and coupon platforms. GoodRx, RxSaver, and NeedyMeds list discounted cash prices at New Mexico pharmacies. Walmart pharmacy in Albuquerque has been priced as low as $9 for a 30-day supply of generic alendronate 70 mg through GoodRx as of early 2026 [3].

Mark Cuban's Cost Plus Drugs. CostPlusDrugs.com lists generic alendronate 70 mg (four tablets per month) at roughly $6 to $8 including dispensing fee, with mail delivery to New Mexico addresses. This represents one of the lowest available prices for the drug nationally [12].

Merck Patient Assistance. Merck's patient assistance program (Merck Helps) provides branded Fosamax at no cost to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Applications are processed through the prescriber's office [13].

New Mexico RxConnect. New Mexico does not operate a standalone state pharmaceutical assistance program for working-age adults, but low-income residents may qualify for Medicaid after documentation of BMD findings, as described above. Patients aged 65 and older on Medicare should apply for the Low Income Subsidy (LIS, also called Extra Help) through the Social Security Administration to reduce Part D cost-sharing to $0 to $4 per month [14].

340B program. Federally Qualified Health Centers (FQHCs) and Indian Health Service (IHS) facilities in New Mexico participate in the 340B drug pricing program, which allows dispensing of alendronate at deeply reduced cost to qualifying patients. Patients served by Zuni Comprehensive Community Health Center, First Choice Community Healthcare, or Hidalgo Medical Services may access 340B pricing directly [15].

Can I Get a Fosamax Prescription via Telehealth in New Mexico?

Telehealth prescribing of alendronate is fully legal in New Mexico. The state enacted broad telehealth parity laws under the New Mexico Telehealth Act (NMSA 1978, Chapter 24, Article 25), and bisphosphonates are not controlled substances, so no in-person visit is required before a provider can prescribe alendronate via a synchronous audio-video telehealth encounter [16].

A telehealth provider must be licensed to practice in New Mexico, must conduct a clinically appropriate evaluation, and must have access to or order the required DXA bone density scan before initiating therapy. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation, BHOF) recommends DXA testing for all women aged 65 and older and for younger postmenopausal women with a FRAX 10-year major osteoporotic fracture probability at or above 8.4% [17].

HealthRX providers licensed in New Mexico can evaluate osteoporosis risk, review uploaded DXA reports, and issue alendronate prescriptions electronically to any New Mexico pharmacy. Follow-up DXA scans are typically ordered at 1 to 2 years after starting therapy to assess bone mineral density response, per American Association of Clinical Endocrinology (AACE) guidelines [18].

How the Clinical Evidence Supports Alendronate as the First-Line Choice

Alendronate's place as a first-line bisphosphonate for postmenopausal osteoporosis rests on data from multiple large randomized controlled trials. The FIT trial published in JAMA (N=2,027, median follow-up 3 years) showed vertebral fracture relative risk reduction of 47% (RR 0.53, P<0.001) [2]. The FIT extension, the FLEX trial (N=1,099, 5-year extension beyond initial FIT), showed that women who discontinued alendronate after 5 years maintained bone density and did not have significantly higher nonvertebral fracture rates compared with women who continued, supporting the concept of a drug holiday for lower-risk patients [19].

The AACE/ACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) are recommended as initial therapy for most patients with postmenopausal osteoporosis due to their efficacy, safety, and cost-effectiveness" [18]. Among oral bisphosphonates, alendronate and risedronate have the strongest fracture endpoint data; ibandronate has vertebral fracture data only.

A 2011 Cochrane review of alendronate for osteoporosis (35 trials, N=11,068) found statistically significant reductions in vertebral fracture risk (relative risk 0.55 to 95% CI 0.45 to 0.67) and hip fracture risk (relative risk 0.63 to 95% CI 0.44 to 0.92) versus placebo, with no significant increase in adverse effects at standard doses [20]. Given a $9 to $15 cash price per month in New Mexico, the cost-per-fracture-prevented calculation strongly favors treatment in patients with confirmed osteoporosis.

Monitoring, Side Effects, and What New Mexico Patients Should Know Before Starting

Esophageal irritation is the most common reason patients stop alendronate. The FDA label requires the medication be taken with a full 8 oz glass of water, and the patient must remain upright for at least 30 minutes afterward [1]. Patients with active esophageal disease, Barrett's esophagus, or inability to sit or stand for 30 minutes are not candidates for oral alendronate; intravenous zoledronic acid (Reclast, 5 mg IV once yearly) is the alternative.

Osteonecrosis of the jaw (ONJ) is rare at oral doses used for osteoporosis. A 2014 systematic review estimated ONJ incidence at roughly 1 in 10,000 to 1 in 100,000 patient-years for oral bisphosphonate use at osteoporosis doses, far lower than rates seen in oncology IV dosing [21]. The American Dental Association recommends that patients inform their dentist of bisphosphonate use but does not recommend stopping alendronate before routine dental procedures [22].

Atypical femoral fracture is a rare but recognized adverse event, estimated at 3.2 to 50 cases per 100,000 person-years in long-term users [23]. The risk increases with duration of use beyond five years, which is why AACE guidelines recommend reassessing fracture risk after three to five years to determine whether a drug holiday is appropriate [18].

Renal function must be reviewed before prescribing. Alendronate is contraindicated in patients with estimated glomerular filtration rate (eGFR) below 35 mL/min/1.73 m2 [1]. New Mexico has a high prevalence of diabetes and chronic kidney disease, particularly in Hispanic and Native American communities, so eGFR screening before initiating therapy is clinically important [24].

Serum calcium and vitamin D should be in the normal range before starting alendronate. Concurrent calcium supplementation (500 to 1 to 000 mg daily in divided doses) and vitamin D3 (800 to 2 to 000 IU daily) are recommended by both BHOF and AACE guidelines to maximize the drug's effect on bone remodeling [17, 18].

New Mexico-Specific Resources for Osteoporosis Care

New Mexico's rural geography means many patients lack easy access to endocrinologists or rheumatologists who specialize in metabolic bone disease. Primary care providers in New Mexico can initiate alendronate therapy based on DXA results without a specialist referral. DXA scans are available at University of New Mexico Hospital (UNMH), Presbyterian Hospital, Lovelace Medical Center, and at several outpatient imaging centers in Albuquerque, with mobile DXA units serving rural counties periodically.

The New Mexico Department of Health does not operate a dedicated osteoporosis screening program, but the USPSTF Grade B recommendation for osteoporosis screening in women 65 and older means DXA scans are covered at no cost-sharing under most commercial and Medicare plans as a preventive service [25]. Women aged 50 to 64 with a FRAX 10-year osteoporosis fracture risk at or above 9.3% also meet USPSTF criteria for covered screening [25].

Patients who are uninsured can access DXA scans at reduced cost through UNM Health's financial assistance program or through IHS facilities for eligible tribal members. The cost of a DXA scan at private imaging centers in New Mexico ranges from $75 to $150 without insurance, and the scan is typically needed only once every one to two years after the baseline.